Tempest says TPST-2003 dual-target CAR-T hits 100% complete response in Phase 1 trials

Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc.

TPST

0.00
  • Tempest Therapeutics presented updated early-stage clinical data at ISCT 2026 on TPST-2003, its dual-targeting CAR-T program in relapsed or refractory multiple myeloma plus POEMS syndrome.
  • Results showed all evaluable patients who had not previously received CAR-T therapy achieved complete remission across both ongoing Phase 1 trials.
  • Safety findings remained supportive, with no severe cytokine release syndrome or neurotoxicity reported in REDEEM-1.
  • Dataset expanded to 44 patients treated across three studies, strengthening evidence base for the program.
  • Company plans FDA discussions on starting a US registrational study later in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060700PRIMZONEFULLFEED9713968) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.